Clinical Cancer Research. 2006 Jun 1;12(11 Pt 2):3581s-8s. [Link]

Everett E. Vokes1, Michael C. Perry2, Hedy L. Kindler1 and Mark R. Green3,4

Authors’ Affiliations: 1 The University of Chicago, Chicago, Illinois; 2 University of Missouri, St. Louis, Missouri; and 3 Medical University of South Carolina, Charleston, South Carolina; and 4 Network for Medical Communication and Research, Atlanta, Georgia

Requests for reprints: Everett E. Vokes, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637-1470. Phone: 773-834-3093; Fax: 773-702-3002; E-mail: .


The Cancer and Leukemia Group B Respiratory Committee has a 30-year track record of clinical investigation in patients with small-cell lung cancer and non–small-cell lung cancer (NSCLC) and mesothelioma. The most widely recognized contributions of the Committee include the early confirmation of the role of concurrent chemoradiotherapy in LD-SCLC, the effect of combination chemotherapy followed by radiation in stage III NSCLC, the introduction of third-generation agents into concurrent chemoradiation for stage III disease, the prospective demonstration of the benefit of treating older (70 years old) and poorer performance status (performance status = 2) patients with first-line combinations for stage IV disease, and the development of the “Herndon prognostic index” to normalize patient characteristics and outcomes in sequential phase II trials of new agents in patients with mesothelioma. Many other contributions have also emerged from the Committee’s clinical trials and correlative science programs. We look forward to making additional critical contributions during future decades of Cancer and Leukemia Group B Respiratory Committee research.